Adults and children aged 6years and older easily recognize multiple images of a familiar face, but often perceive two images of an unfamiliar face as belonging to different identities. Here we examined the process by which a newly encountered face becomes familiar, defined as accurate recognition of multiple images that capture natural within-person variability in appearance. In Experiment 1 we examined whether exposure to within-person variability in appearance helps children learn a new face. Children aged 6-13years watched a 10-min video of a woman reading a story; she was filmed on a single day (low variability) or over three days, across which her appearance and filming conditions (e.g., camera, lighting) varied (high variability). After familiarization, participants sorted a set of images comprising novel images of the target identity intermixed with distractors. Compared to participants who received no familiarization, children showed evidence of learning only in the high-variability condition, in contrast to adults who showed evidence of learning in both the low- and high-variability conditions. Experiment 2 highlighted the efficiency with which adults learn a new face; their accuracy was comparable across training conditions despite variability in duration (1 vs. 10min) and type (video vs. static images) of training. Collectively, our findings show that exposure to variability leads to the formation of a robust representation of facial identity, consistent with perceptual learning in other domains (e.g., language), and that the development of face learning is protracted throughout childhood. We discuss possible underlying mechanisms.
Adults' ability to match identity in images of unfamiliar faces is impaired for other- compared with own-race faces; their ability to match identity in images of familiar faces is independent of face race. Exposure to within-person variability in appearance plays a key role in face learning. Past research suggests that children need exposure to higher levels of variability than adults to learn a new face-a difference that has been attributed to experience. We predicted that adults' limited experience with other-race faces would result in their needing exposure to higher levels of variability when learning other- compared with own-race faces. We introduced adults to four new identities (two own-race; two other-race) in one of the three conditions: a single image, a low-variability video (filmed on 1 day), or a high-variability video (filmed across 3 days). Adults' ability to recognize new instances of learned identities improved in the low-variability condition for own-race faces but only in the high-variability condition for other-race faces. We discuss learning mechanisms that might drive this difference-a difference we attribute to experience.
A super-enhancer at the retinoic acid receptor alpha (RARA) gene is associated with RARA mRNA overexpression in approximately 30% of non-acute promyelocytic leukemia (non APL) acute myeloid leukemia (AML) and in approximately 50% of myelodysplastic syndromes (MDS). RARA overexpression is an actionable target for treatment with tamibarotene, an oral potent and selective RARα agonist. Sensitivity to the RARα agonist tamibarotene was demonstrated in RARA-high but not RARA-low preclinical AML models. The combination of oral tamibarotene plus azacitidine was evaluated in a Phase 2 clinical study in 51 newly diagnosed unfit AML patients identified as RARA-positive (N = 22) or RARA-negative (N = 29) for RARA mRNA overexpression in peripheral blasts with a blood-based biomarker test. In 18 response evaluable RARA-positive patients, complete remission/complete remission with incomplete hematologic recovery (CR/CRi) rate was 61%, CR rate was 50%, and time to initial composite CR was rapid at 1.2 months. Transfusion independence was attained by 72% of RARA-positive patients. In contrast, 28 response evaluable RARA-negative patients had response rates that were consistent with azacitidine monotherapy. Tamibarotene in combination with azacitidine was well-tolerated. The majority of non-hematologic adverse events (AEs) were low grade and hematologic AEs were comparable to single agent azacitidine, demonstrating that there was no additional myelosuppression when tamibarotene was combined with azacitidine. These results support further evaluation of tamibarotene-based treatment strategies in AML and MDS patients with RARA overexpression to provide a targeted approach with the goal of improving patient outcomes. This trial is registered at www.clinicaltrials.gov as NCT02807558.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.